Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2019-02-01
2022-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals
NCT04960527
The Effect of Tart Cherry Juice on Risk of Gout Attacks
NCT03621215
Montmorency Cherry Juice and Uric Acid Metabolism
NCT01825070
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
NCT03636529
Influence of Tart Cherry Juice Intervention on Vascular Function
NCT04840160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tart cherry concentrate 60 mL
Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
Tart cherry extract 60 mL
Subjects will receive a single 60 mL oral dose of tart cherry extract.
Tart cherry extract 120 mL
Subjects will receive a single 120 mL oral dose of tart cherry extract.
Tart cherry concentrate 120 mL
Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
Tart cherry extract 60 mL
Subjects will receive a single 60 mL oral dose of tart cherry extract.
Tart cherry extract 120 mL
Subjects will receive a single 120 mL oral dose of tart cherry extract.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tart cherry extract 60 mL
Subjects will receive a single 60 mL oral dose of tart cherry extract.
Tart cherry extract 120 mL
Subjects will receive a single 120 mL oral dose of tart cherry extract.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any history of malignancy
* History of any pancreatic or biliary tract disease
* Significant Anemia
* History of significant renal (sCr \> 1.5 mg/dL)
* Hepatic disease (liver enzymes 3 times upper limit of normal)
* Any active gastrointestinal condition
* History of large bowel resection for any reason
* Use of cherry juice concentrate or consumption of cherries within 14 days
* Personal or inherited bleeding disorders or currently on anticoagulation
* Women of childbearing age not on oral contraceptives
* Women who are pregnant or nursing
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rutgers, The State University of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Naomi Schlesinger, MD, Professor of Medicine
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naomi Schlesinger, MD
Role: PRINCIPAL_INVESTIGATOR
Robert Wood Johnson Medical School/ Rutgers RWJMS Gout Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro20170001180
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.